Trial Watch: Adoptive cell transfer for anticancer immunotherapy

Following up the Trial Watch that we published on this topic in the third issue of OncoImmunology (May 2012), here we summarize the latest developments in ACT research, covering both high-impact studies that have been published during the last 13 months and clinical trials that have been initiated in the same period to assess the antineoplastic profile of this form of cellular immunotherapy.”


Targeted therapies of solid cancers: new options, new challenges

Purpose of review: The landscape of medical oncology is filled with approvals of new anticancer agents, the majority of which are targeted agents. This shift in therapies raises multiple challenges including the appearance of new toxicities, the need for biomarkers, the emergence of genomics and the evolution of cancer molecular imaging.”


Nymox Prostate Cancer Trial Receives Positive Interim Safety Review From Independent Data Monitoring Committee

“Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that the Independent Data Monitoring Committee for the Company’s Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) has reported a third positive analysis of safety data from the clinical trial. The Independent Data Monitoring Committee assessed all patients to date who had received NX-1207 for treatment of their localized prostate cancer.”


Targeted therapies of solid cancers: new options, new challenges

Purpose of review: The landscape of medical oncology is filled with approvals of new anticancer agents, the majority of which are targeted agents. This shift in therapies raises multiple challenges including the appearance of new toxicities, the need for biomarkers, the emergence of genomics and the evolution of cancer molecular imaging.”


Targeted therapies of solid cancers: new options, new challenges

Purpose of review: The landscape of medical oncology is filled with approvals of new anticancer agents, the majority of which are targeted agents. This shift in therapies raises multiple challenges including the appearance of new toxicities, the need for biomarkers, the emergence of genomics and the evolution of cancer molecular imaging.”


Genetic testing may be used to identify BPH patients with increased risk of prostate cancer


The E3 Ubiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity

  • A subset of chromatin-bound AR is regulated by Siah2, in concert with NCOR1.
  • Siah2 regulates select AR target genes implicated in PCa proliferation and motility.
  • Growth of castration-resistant PCa models is inhibited upon Siah2 knockdown.
  • Siah2 expression is reduced during ADT and increased in CRPC.

New Study Evaluates Incidence and Mortality of Prostate Cancer After Termination of PSA-Based Screening

Men who participate in biennial PSA based screening have a lower risk of being diagnosed as well as dying from prostate cancer up to 9 years after their last PSA test, according to the results of a new study to be presented at the 28th Annual EAU Congress in Milan.


Hsp27 regulates epithelial mesenchymal transition, metastasis and circulating tumor cells in prostate cancer

We observed a correlation between Hsp27 and Twist in PCa patients, with Hsp27 and Twist expression each elevated in high grade PCa tumors. Hsp27 inhibition by OGX-427, an antisense therapy currently in Phase II trials, reduced tumor metastasis in a murine model of PCa. More importantly, OGX-427 treatment decreased the number of circulating tumor cells in patients with metastatic castration-resistant PCa in a Phase I clinical trial. Overall, this study defines Hsp27 as a critical regulator of IL-6 dependent and independent EMT, validating this chaperone as a therapeutic target to treat metastatic PCa.”